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Siu et al. have comprehensively assessed the rapidly changing regulation and reimbursement 
environment for biologicals and biosimilars in Canada and the resultant implications. 
 
Brian Godman, Eleonora Allocati and Evelien Moorkens review the paper by Siu et al. regarding the 
evolving regulatory and reimbursement landscape in Canada (1), and subsequently link these within 
the broader global context of biosimilar market access to stimulate future activities and debates in this 
important area. This includes the current and potential market value of biosimilars, their regulatory 
and reimbursement environments as well as ongoing initiatives across countries to enhance their 
utilisation to maximise potential savings. In addition, the potential sustainability of appreciable 
discounts among both originator and biosimilar manufacturers. 
 
Siu et al. point out that biologics are now commonly prescribed medicines for a wide variety of 
disease areas including diabetes, immunological diseases such as arthritis, inflammatory bowel 
disease, and psoriasis, as well as for a number of cancers (1-4). Their high prices coupled with the 
prevalence of these diseases have resulted in considerable sales. Worldwide sales of cancer 
medicines, many of which are biologicals, was US$107billion in 2015 and rising (5, 6). The global anti 
TNF market was valued at US$ 40.4 billion in 2017, and expected to expand at 2.54% per year with 
Europe and the US currently accounting for 87.7% of sales (7). Within this, worldwide sales of 
adalimumab were US$ 17.6 billion in 2017, rising to nearly US$ 20 million in 2018 thereby making it 
the world’s best selling medicine, with infliximab sales at US$ 5.9 billion in 2017 and etanercept at 
US$ 5.8 billion in 2017 (8, 9). In Canada in 2017, biologicals accounted for 21.6% of overall public 
healthcare expenditure with the anti-TNF medicines accounting for 8.2% of total expenditure (1). This 
compares with the US where biologicals currently account for 37% of net drug spending (10). In the 
UK, anti-TNF medicines are also one of the highest spend areas within high cost medicines, with 
GB£780 million spent in England in 2018 (11), and in Germany, adalimumab was the top selling 
medicine in 2017 with net costs to the statutory health insurance system of €975 million (12). 
Consequently, the introduction of biosimilars, especially in oncology and immunological diseases, 
should be of considerable interest to payers of healthcare and patients world-wide. We have seen 
limited use to date of biological medicines in many Central and Eastern European countries versus 
Western European countries due to their high costs and co-payments (13-15). Consequently, 
biosimilars should help address this as prices fall. A competitive market should also bring down the 
cost of biosimilar insulins, helping many patients in low and middle income countries currently denied 
such treatments (16).  
 
As a result of the current and envisaged sales of biological medicines coupled with ongoing initiatives, 
we are seeing considerable growth in the availability and use of biosimilars especially in China and 
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Europe (17-20). This will help increase their world-wide sales from approximately US$4 billion in 2018 
(21). Competition, with the resultant impact on overall expenditures, should intensify as many 
biological medicines that are currently used first or second line in treatment regimens lose their patent 
benefitting patients and payers (22). 
 
Siu et al. point out appreciable changes in the regulatory and HTA domains in the biosimilar 
environment in Canada in recent years to enhance their availability and promote their uptake (1). This 
includes Health Canada in 2015 launching a pilot programme to provide manufacturers with the ability 
to discuss their biosimilar with Health Canada. In 2017, Health Canada laid out a Regulatory Review 
of Drugs and Devices which included a project to improve access to biologics (biosimilars and non-
biosimilars) by increasing their regulatory review capacity (1). This should result in a more secure 
supply of biologic drugs and more affordable biologics. In addition, Health Canada and HTA 
organisations in Canada as well as INESS in Quebec began collaborating in 2018 to better align 
review processes including biosimilars to reduce duplication and time lags between regulatory 
approval and reimbursement (1). Heath Canada also intends to implement an updated naming 
convention for biologics including the product’s brand name, International non-proprietary name 
(INN), and the Drug Identification number (DIN), to support a clear distinction between biologics 
including biosimilars to enhance adverse event tracking (1). There have also been initiatives in other 
countries to enhance earlier access to biosimilars (20, 21, 23-26) although further developments are 
being proposed (27). Interestingly, whilst modifications to the manufacturing process of originator 
biologic drugs are common, regulators have very rarely required clinical studies to assess similarities 
even in the case of major manufacturing changes (28, 29).  
 
With respect to reimbursing biosimilars, a number of significant changes have taken place recently in 
Canada to ease the situation. In Canada, the CADTH (Canadian Agency for Drugs and Technologies 
in Health) Common Drug Review (CDR) plays an important role in deciding whether medicines will be 
eligible for public reimbursement, with the Provinces subsequently typically making the final decision 
based on CDR recommendations (30). In May 2019, CADTH announced that as of June 1, 2019, it 
would no longer routinely review biosimilars via its CDR and pCODR (pan-Canadian Oncology Drug 
Review) programmes to streamline access (1). A similar situation is seen in Quebec with INESS. The 
pan-Canadian Pharmaceutical Alliance (pCPA) subsequently uses its combined purchasing power to 
improve access and increase the cost-effectiveness of medicines, similar to cross country 
collaborations in Europe (31-34). In 2016, pCPA launched a more comprehensive biosimilar policy 
and in 2018 released a Biologics Policy Directive in which biologic drugs for which biosimilars are 
already reimbursed as well as any new biosimilar will not be considered for reimbursement unless 
there are transparent price reductions to the lowest list price, providing an exemplar to others (1). In 
addition, the potential for tiered pricing in certain therapeutic areas, which is likely to lead to 
increasing discounts as more biosimilars are launched. Manitoba was the first Canadian Province to 
instigate tiered arrangements in which biologic-naive patients must first be prescribed a biosimilar or 
an approved biologic where no biosimilar exists (1). Private Insurers in Canada are also now offering 
preferential coverage for biosimilars leading to average savings of CAD$8,500 per participating 
member per year (1). Such initiatives should help boost the use of biosimilars in Canada along with 
educational, awareness and other initiatives, with biosimilar use currently lagging behind Europe (1, 
19).  
 
Biosimilars Canada has also recently developed a centralised patient support service platform to 
assist manufacturers and patients (1). Policies regarding switching should also help enhance the use 
of biosimilars in Canada along with collecting real-world evidence to help ally current fears (1). There 
have been considerable concerns with patients being switched between an originator biological 
medicine and a biosimilar across countries as well as indication extrapolation especially with respect 
to the risk of immunogenicity-related safety issues and diminished efficacy (17, 35). However, an 
appreciable number of studies have now shown that such risks are unchanged when switching 
between an originator and a biosimilar (11, 21, 36-44). As a result, patient and physician 
organisations in Canada are now supporting non-medical switching (1), similar to initiatives among 
European countries such as France (45). The growing body of evidence for biosimilars is also leading 
to suggestions to modify the current lengthy approval process and costs to enhance earlier access 
and strengthen competition (46). There are though still concerns with switching among physicians that 
need to be addressed with education as these can negatively impact on their future utilisation (47-49). 
Additional monitoring of patient outcomes in routine clinical practice should help further reduce 
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possible concerns as well as potentially reduce the need for comparative clinical efficacy evidence as 
more originators lose their patents. This should reduce the investment needed for developing new 
biosimilars, and combined with developments in manufacturing (50), should help reduce future prices. 
 
A number of other initiatives have also recently been undertaken in Canada to enhance the utilisation 
of biosimilars. This includes the pan-Canadian Oncology Biosimilars Initiative to enhance successful 
adoption of biosimilars in oncology. British Columbia launched its Biosimilars Initiative in May 2019 
promoting switching, with the savings used to lower premiums and co-pays where pertinent (1). Other 
Provinces are likely to follow.  
 
We have also seen initiatives among other countries to enhance the use of biosimilars. Moorkens et 
al. and Vogler et al. have summarised these for Europe as well as provided future guidance to further 
enhance their uptake (51, 52). More recently, Simoens et al. gave guidance on additional measures 
that could be introduced in Europe to fully realise the potential of biosimilars (53). We are also seeing 
prescribing targets for biosimilars among European countries including national frameworks (54-57). 
However, there are still limited initiatives in some countries including Japan where currently no 
position statement regarding biosimilars has been included in treatment guidelines for any of the 
cancer societies (58). This may change though with increasing pressure on resources and with the 
Japanese government now reviewing supportive measures for biosimilars (58). Smeeding et al. 
recently highlighted a number of issues that payers in the US should consider as part of any strategy 
to increase the use of biosimilars (59).   
 
Ongoing initiatives across countries, including both supply-side and demand-side measures, have 
increased potential savings from biosimilars. Siu et al. suggest that by the third year of entry, potential 
savings from biosimilars in Canada could range from 13-43% for acute use products such as 
Granulocyte Colony-stimulating Factors (G-CSF) and erythropoietin (EPO) and 8-43% for chronic-use 
products, e.g. anti-TNFs (1). This is helped by price reductions for biosimilars in Canada ranging 
between 17% and 50% from the originator.  
 
A number of European countries have introduced price-link policies for biosimilars to lower their prices 
and enhance savings, with other countries instigating measures such as tendering to lower prices (52, 
60, 61). For instance, tendering among hospitals in Norway resulted in a 72% discount compared to 
its list (60), and tendering in the UK will result in GB£300million (approximately $386 million) savings 
from currently GB£400 million-per-year (approximately $514 million) spent on adalimumab (62). In 
Germany, the current high use of adalimumab and anticipated savings resulted in biosimilars 
accounting for 28% of total prescriptions of adalimumab within eight weeks of launch (12). In the US, 
it is estimated that biosimilars will reduce direct spending on biologic drugs by $54 billion from 2017 to 
2026 (10, 63); with savings likely to be higher with greater discounts than 20% to 30% currently seen 
(10). Substantial discounts for biosimilars across Europe, greater than initial considerations (61), 
coupled with demand-side measures, have already resulted in their appreciably increased use in 
recent years. In some cases and countries in Europe, biosimilars now account for the total market, 
e.g. EPO and G-CSF, providing guidance to others (19).  
 
However, there are concerns that originators are starting to substantially lower their prices potentially 
affecting future biosimilar availability and the sustainability of the market place as seen recently with 
adalimumab (9, 19, 64). In addition, we are seeing originator companies defending manufacturing and 
other patents, as well as seeking to instigate hurdles in the US making it more difficult for insurers to 
place biosimilars on formularies in order to disrupt the biosimilar market (10, 65, 66). Originator 
companies are also developing new formulations of their biologicals to try and further disrupt the 
biosimilar market building on previous evergreening tactics (19, 67). There are also suggestions to 
lower the prices of originators in countries such as Belgium and the US over time, negating the need 
for biosimilars to further interfere with this market (68). We will continue to monitor these 
developments and their implications. 
 
In conclusion, Siu et al. have provided a comprehensive review of current and planned policies in 
Canada to enhance the use of biosimilars at competitive prices to benefit payers and patients. This is 
important for disease areas such as cancer with ever increasing prices for new medicines, which 
potentially threaten the sustainability of healthcare systems (69, 70). It is also increasingly likely that 
health authorities will start re-assessing prices and potential discounts for on-patent medicines for 
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oncology and immunological diseases as more standard medicines used for pricing negotiations lose 
their patents (6, 71). Siu et al. also remind key stakeholders to continually monitor developments with 
biosimilars including both supply- and demand-side initiatives as well as encourage countries to learn 
from each other to enhance their uptake. This is critical for health authorities with the instigation of 
disruptive tactics such as in the Netherlands with AbbVie and in the US with hurdles such as rebates 
and other strategies with insurers to limit biosimilar use. In addition, payers need to monitor the 
development of new formulations by originator manufacturers and plan for the implications.  
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